Author

Emily Knight

Observed names: Emily A Knight, Emily A. Knight, Emily A. Knight, RN, BSN, OCN, Knight, Emily

Observed institutions: Canterbury Christ Church University, Emory University, Oral Roberts University, Mayo Clinic in Arizona, Winship Cancer Institute, University College London, Clemson University

OpenAlex ID: A5046860840

Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval

2013 · Holly Geyer, Keith Cannon, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 23

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

2015 · Guillermo Garcia-Manero, Raoul Tibes, et al. · Investigational New Drugs · 21

Using water–solvent systems to estimate in vivo blood–tissue partition coefficients

2015 · Caitlin E. Derricott, Emily A. Knight, et al. · Chemistry Central Journal · 12

PDF

Enolase Inhibitors as Early Lead Therapeutics against Trypanosoma brucei

2023 · Colm P. Roster, Danielle LaVigne, et al. · Pathogens · 9

PDF

Synthesis of novel and potent vorapaxar analogues

2016 · Emily Knight, Eifion Robinson, et al. · Organic & Biomolecular Chemistry · 8

PDF

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies

2015 · Raoul Tibes, Heidi E. Kosiorek, et al. · Blood · 8

Identification of an active metabolite of PAR-1 antagonist RWJ-58259 and synthesis of analogues to enhance its metabolic stability

2016 · Eifion Robinson, Emily Knight, et al. · Organic & Biomolecular Chemistry · 7

PDF

Kinome scale profiling of venom effects on cancer cells reveals potential new venom activities

2020 · Danielle McCullough, Cristina Atofanei, et al. · Toxicon · 5

Measuring Dynamic Glycosomal pH Changes in Living Trypanosoma brucei

2024 · Daniel Call, Sabrina S. Pizarro, et al. · Journal of Visualized Experiments · 2

PDF

Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial

2013 · Veena Fauble, Robyn M. Emanuel, et al. · Blood · 2

Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience After FDA Approval

2012 · Holly Lynn Geyer, Emily Knight, et al. · Blood · 2

Blood transfusion and management of acute heavy menstrual bleeding (BROWNIE): a retrospective and observational cost analysis service evaluation

2025 · Jhia Jiat Teh, Tia Hunjan, et al. · The Lancet Obstetrics Gynaecology & Women s Health · 1

A molecular modeling study on the structure and vibrational properties of the chemotherapy drug letrozole

2017 · K. Balci, Y. Akkaya, et al.

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors.

2016 · Emily A Knight, Sylvia Osunsuyi-Fagbemi, et al. · PubMed

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors

2015 · Emily A. Knight, RN, BSN, OCN, Sylvia Osunsuyi-Fagbemi, RN, et al. · Journal of the Advanced Practitioner in Oncology

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors

2015 · Emily A. Knight, RN, BSN, OCN, Sylvia Osunsuyi-Fagbemi, RN, BSN, OCN, et al. · Journal of the Advanced Practitioner in Oncology

Modeling Radiation Effectiveness for Inactivation of Bacillus Spores

2015 · Emily Knight

MOESM1 of Using water–solvent systems to estimate in vivo blood–tissue partition coefficients

2015 · Derricott, Caitlin, Knight, Emily, et al. · Figshare

Modeling Thermal Inactivation of Bacillus Spores

2012 · Emily Knight · Defense Technical Information Center (DTIC)

Works count: 19

Citation count: 100

H-index: 7

I10-index: 3